EP1616181A4 - Polypeptides lies aux peptides natriuretiques, procedes d'identification et d'utilisation de ces derniers - Google Patents

Polypeptides lies aux peptides natriuretiques, procedes d'identification et d'utilisation de ces derniers

Info

Publication number: EP1616181A4
Authority: EP; European Patent Office
Prior art keywords: identification; methods; natriuretic peptides; polypeptides related; polypeptides
Prior art date: 2003-04-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP04750349A

Other languages

German (de)

English (en)

Other versions

EP1616181A2 (fr

EP1616181B1 (fr

Inventor

Kenneth F Buechler

Eric Thomas Fung

Tai-Tung Yip

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Alere San Diego Inc

Aspira Womens Health Inc

Original Assignee

Ciphergen Biosystems Inc

Biosite Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-17

Filing date

2004-04-19

Publication date

2006-09-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33313107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1616181(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-04-17 Priority claimed from US10/419,059 external-priority patent/US20030219734A1/en

2004-04-19 Application filed by Ciphergen Biosystems Inc, Biosite Inc filed Critical Ciphergen Biosystems Inc

2006-01-18 Publication of EP1616181A2 publication Critical patent/EP1616181A2/fr

2006-09-06 Publication of EP1616181A4 publication Critical patent/EP1616181A4/fr

2009-08-12 Application granted granted Critical

2009-08-12 Publication of EP1616181B1 publication Critical patent/EP1616181B1/fr

2024-04-19 Anticipated expiration legal-status Critical

Status Revoked legal-status Critical Current

Links

108020001621 Natriuretic Peptide Proteins 0.000 title 1
102000004571 Natriuretic peptide Human genes 0.000 title 1
239000000692 natriuretic peptide Substances 0.000 title 1
229920001184 polypeptide Polymers 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
Endocrinology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)
Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

EP04750349A 2003-04-17 2004-04-19 Polypeptides lies aux peptides natriuretiques, procedes d'identification et d'utilisation de ces derniers Revoked EP1616181B1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10/419,059 US20030219734A1 (en)	2001-04-13	2003-04-17	Polypeptides related to natriuretic peptides and methods of their identification and use
US46635803P	2003-04-28	2003-04-28
PCT/US2004/012067 WO2004094460A2 (fr)	2003-04-17	2004-04-19	Polypeptides lies aux peptides natriuretiques, procedes d'identification et d'utilisation de ces derniers

Publications (3)

Publication Number	Publication Date
EP1616181A2 EP1616181A2 (fr)	2006-01-18
EP1616181A4 true EP1616181A4 (fr)	2006-09-06
EP1616181B1 EP1616181B1 (fr)	2009-08-12

Family

ID=33313107

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP04750349A Revoked EP1616181B1 (fr)	2003-04-17	2004-04-19	Polypeptides lies aux peptides natriuretiques, procedes d'identification et d'utilisation de ces derniers

Country Status (5)

Country	Link
US (2)	US7341838B2 (fr)
EP (1)	EP1616181B1 (fr)
JP (1)	JP2006527190A (fr)
CA (1)	CA2522709A1 (fr)
WO (1)	WO2004094460A2 (fr)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6627404B1 (en) *	1995-04-18	2003-09-30	Biosite, Inc.	Methods for improving the recovery of troponin I and T in membranes, filters and vessels
US6991907B1 (en) *	1995-04-18	2006-01-31	Biosite, Inc.	Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays
US20040176914A1 (en) *	2001-04-13	2004-09-09	Biosite Incorporated	Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
US20030199000A1 (en) *	2001-08-20	2003-10-23	Valkirs Gunars E.	Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7713705B2 (en) *	2002-12-24	2010-05-11	Biosite, Inc.	Markers for differential diagnosis and methods of use thereof
US20040253637A1 (en) *	2001-04-13	2004-12-16	Biosite Incorporated	Markers for differential diagnosis and methods of use thereof
US7632647B2 (en) *	2001-04-13	2009-12-15	Biosite Incorporated	Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
US7524635B2 (en) *	2003-04-17	2009-04-28	Biosite Incorporated	Methods and compositions for measuring natriuretic peptides and uses thereof
US20040219509A1 (en) *	2001-08-20	2004-11-04	Biosite, Inc.	Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7608406B2 (en) *	2001-08-20	2009-10-27	Biosite, Inc.	Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040209307A1 (en) *	2001-08-20	2004-10-21	Biosite Incorporated	Diagnostic markers of stroke and cerebral injury and methods of use thereof
FR2843396B1 (fr) *	2002-08-07	2005-04-15	Bio Rad Pasteur	Anticorps specifiques pour le diagnostic de l'insuffisance cardiaque
WO2004097368A2 (fr) *	2003-04-28	2004-11-11	Ciphergen Biosystems, Inc.	Dosages immunologiques ameliores
GB2403533A (en) *	2003-06-30	2005-01-05	Orion Corp	Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
PL2348114T3 (pl)	2004-04-21	2019-08-30	Alexion Pharmaceuticals, Inc.	Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
FR2882171A1 (fr) *	2005-02-14	2006-08-18	France Telecom	Procede et dispositif de generation d'un arbre de classification permettant d'unifier les approches supervisees et non supervisees, produit programme d'ordinateur et moyen de stockage correspondants
US7731965B2 (en) *	2005-02-17	2010-06-08	Abbott Lab	Human ring specific BNP antibodies
US20070087387A1 (en) *	2005-04-21	2007-04-19	Prasad Devarajan	Method for the Early Detection of Renal Disease Using Proteomics
WO2007047614A2 (fr) *	2005-10-14	2007-04-26	Scios Inc.	Probnp glycosyle
US7939069B2 (en)	2005-11-09	2011-05-10	Abbott Laboratories	Human BNP immunospecific antibodies
WO2007056507A1 (fr)	2005-11-09	2007-05-18	Abbott Laboratories	Anticorps immunospecifiques du bnp humain
WO2007079392A2 (fr) *	2005-12-30	2007-07-12	The Trustees Of Columbia University In The City Of New York	Dosage en temps réel de facteurs neuro-humoraux pour évaluer un stress cardio-vasculaire
US20070224643A1 (en) *	2006-03-09	2007-09-27	Mcpherson Paul H	Methods and compositions for the diagnosis of diseases of the aorta
JP2009531712A (ja) *	2006-03-23	2009-09-03	デグスマンブレイヤー、エメリタ	アポリポタンパク質フィンガープリント技術
US20080118924A1 (en) *	2006-05-26	2008-05-22	Buechler Kenneth F	Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases
ATE528411T1 (de)	2006-06-07	2011-10-15	Otago Innovation Ltd	Diagnoseverfahren und -marker
WO2008030122A1 (fr)	2006-09-07	2008-03-13	University Of Otago	Biomarqueurs
US20080064045A1 (en) *	2006-09-07	2008-03-13	Huaiqin Wu	Biomarker fragments for the detection of human BNP
US7842472B2 (en)	2006-11-14	2010-11-30	Alere International	Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
US8524462B2 (en) *	2006-11-14	2013-09-03	Alere San Diego, Inc.	Methods and compositions for diagnosis and prognosis of renal artery stenosis
WO2008076994A2 (fr) *	2006-12-18	2008-06-26	Anthera Pharmaceuticals, Inc.	Méthodes de détection et de mesure des taux de phospholipase a2 sécrétoire (spla2) dans les liquides biologiques
ES2401741T3 (es) *	2007-05-08	2013-04-24	Abbott Laboratories	Ensayo de péptido natriurético de tipo B humano que tiene una reducida reactividad cruzada con otras formas péptidicas
EP2174143B1 (fr)	2007-08-03	2011-06-22	B.R.A.H.M.S GmbH	Procede de stratification du risque chez des patients ayant une maladie associee avec des coronaropathies
EP2101178A1 (fr) *	2008-03-12	2009-09-16	BRAHMS Aktiengesellschaft	Utilisation de procalcitonine (PCT) pour le pronostic suivant des syndromes coronaires aigus
WO2010012834A1 (fr) *	2008-08-01	2010-02-04	Bio-Rad Pasteur	Méthode de diagnostic in vitro de l'accident vasculaire cérébral
FR2919611B1 (fr) *	2007-08-03	2009-10-23	Bio Rad Pasteur Sa	Nouvel epitope du bnp (1-32) et anticorps diriges contre cet epitope
WO2010012509A1 (fr) *	2008-08-01	2010-02-04	Bio-Rad Pasteur	Procédé pour le diagnostic in vitro d'un accident vasculaire cérébral
US9482677B2 (en)	2008-02-27	2016-11-01	Scios Inc.	Method, composition and device for sampling natriuretic peptides in a biological fluid
JP2011516038A (ja)	2008-03-12	2011-05-26	オタゴイノベーションリミテッド	バイオマーカー
ES2666725T3 (es) *	2008-03-12	2018-05-07	Otago Innovation Limited	Biomarcadores
EP2294079A2 (fr) *	2008-05-16	2011-03-16	Pronota NV	Nouveaux polypeptides apparentés à des peptides natriurétiques de type b et leurs procédés d'identification et d'utilisation
US20090286256A1 (en) *	2008-05-19	2009-11-19	Abbott Laboratories	Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides
US20090286329A1 (en) *	2008-05-19	2009-11-19	Abbott Laboratoires	Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides
JP5550021B2 (ja) *	2008-08-28	2014-07-16	株式会社島津製作所	血液試料を用いて心筋虚血状態を評価する方法
US20110270530A1 (en) *	2008-12-08	2011-11-03	Seok-Won Lee	Combined natriuretic peptide assays
WO2010086382A1 (fr)	2009-01-30	2010-08-05	Pronota N.V.	Cible pour le traitement d'une insuffisance cardiaque aiguë
WO2010086384A1 (fr)	2009-01-30	2010-08-05	Pronota N.V.	Cible pour le traitement d'une insuffisance cardiaque aiguë
WO2010086697A1 (fr) *	2009-01-30	2010-08-05	Bio-Rad Pasteur	Procédé de diagnostic in vitro d'accident vasculaire cérébral
EP2391892B1 (fr)	2009-01-30	2017-01-18	Mycartis N.V.	Biomarqueur pour le diagnostic d'une insuffisance cardiaque aiguë et utilisations associées
JP5795256B2 (ja) *	2009-07-31	2015-10-14	バイオ−ラッド・イノベーションズＢｉｏ−ＲａｄＩｎｎｏｖａｔｉｏｎｓ	卒中のインビトロ診断のための方法
CA2776978A1 (fr)	2009-10-21	2011-04-28	Pronota N.V.	Biomarqueur pour le diagnostic, la prediction et/ou le pronostic d'insuffisance cardiaque aigue et utilisations de celui-ci
EA201290311A1 (ru) *	2009-11-13	2012-12-28	БиДжи МЕДИСИН, ИНК.	Факторы риска и прогнозирование инфаркта миокарда
EP2924439B1 (fr)	2010-03-26	2017-02-01	MyCartis N.V.	Ltbp2 comme biomarqueur pour la prediction ou le pronostic de la mortalite
CN101864525A (zh) *	2010-04-27	2010-10-20	中国神华能源股份有限公司	一种由粉煤灰提取镓的方法
CN101838738A (zh) *	2010-04-27	2010-09-22	中国神华能源股份有限公司	一种由粉煤灰提取镓的方法
NZ707637A (en)	2010-07-19	2016-09-30	Otago Innovation Ltd	Signal biomarkers
DE102010047582A1 (de) *	2010-10-07	2012-04-12	Justus-Liebig-Universität Giessen	Stoffe und deren Verwendung zur Beeinflussung natriuretischer Peptidrezeptoren
EP2601531A1 (fr) *	2010-08-04	2013-06-12	IDEXX Laboratories, Inc.	Détection des produits de dégradation du nt-probnp canin
US8679474B2 (en)	2010-08-04	2014-03-25	StemBios Technologies, Inc.	Somatic stem cells
EP2601532B1 (fr)	2010-08-06	2016-01-27	Mycartis N.V.	Utilisation de perlecan en tant que biomarqueur d'un dysfonctionnement rénal
EP2658979B1 (fr)	2010-12-27	2018-02-14	Alexion Pharmaceuticals, Inc.	Compositions contenant des peptides natriurétiques et leurs méthodes d'utilisation
EP2678002A2 (fr)	2011-02-25	2014-01-01	Medtronic, Inc.	Thérapie pour néphropathie et/ou insuffisance cardiaque
US8481333B2 (en)	2011-05-31	2013-07-09	Idexx Laboratories, Inc.	Detection of degradation products of feline NT-proBNP
EP2750697A4 (fr)	2011-09-02	2015-03-25	Medtronic Inc	Compositions de peptides natriurétiques chimériques et procédés de préparation
EP2766734A1 (fr)	2011-10-14	2014-08-20	Pronota NV	Pro-cathepsine l et cathepsine l en tant que biomarqueurs de l'ischémie
WO2013141716A1 (fr)	2012-03-20	2013-09-26	Christopher Joseph Pemberton	Biomarqueurs
US10052366B2 (en)	2012-05-21	2018-08-21	Alexion Pharmaceuticsl, Inc.	Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
JP6495174B2 (ja)	2012-12-06	2019-04-03	ステムバイオステクノロジーズ，インコーポレイテッド	Ｌｇｒ５＋体性幹細胞
EP2746769A1 (fr) *	2012-12-21	2014-06-25	Stembios Technologies, Inc.	Procédé pour évaluer l'effet d'action sur un sujet basé sur des dynamiques cellulaires de tiges
DK3387898T3 (da) *	2013-03-15	2020-08-03	Mayo Found Medical Education & Res	Identificering og monitorering af monoklonale immunglobuliner ved hjælp af molekylvægt
US10822596B2 (en)	2014-07-11	2020-11-03	Alexion Pharmaceuticals, Inc.	Compositions and methods for treating craniosynostosis
WO2016090251A1 (fr)	2014-12-05	2016-06-09	Alexion Pharmaceuticals, Inc.	Traitement de crise avec une phosphatase alcaline recombinée
US10603361B2 (en)	2015-01-28	2020-03-31	Alexion Pharmaceuticals, Inc.	Methods of treating a subject with an alkaline phosphatase deficiency
AU2016308624B2 (en)	2015-08-17	2022-06-23	Alexion Pharmaceuticals, Inc.	Manufacturing of alkaline phosphatases
EP3355904A4 (fr)	2015-09-28	2019-06-12	Alexion Pharmaceuticals, Inc.	Identification de régimes posologiques efficaces pour une thérapie de l'hypophosphatasie de remplacement de l'enzyme phosphatase alcaline non spécifique à des tissus (tnsalp)
JP2018533571A (ja)	2015-10-30	2018-11-15	アレクシオンファーマシューティカルズ，インコーポレイテッド	患者の頭蓋縫合早期癒合症を治療するための方法
EP3426286A4 (fr)	2016-03-08	2019-12-04	Alexion Pharmaceuticals, Inc.	Méthodes de traitement de l'hypophosphatasie chez l'enfant
WO2017173395A1 (fr)	2016-04-01	2017-10-05	Alexion Pharmaceuticals, Inc.	Méthodes de traitement de l'hypophosphatasie chez les adolescents et les adultes
KR20180125979A (ko)	2016-04-01	2018-11-26	알렉시온 파마슈티칼스, 인코포레이티드	알칼리성 포스파타아제로 근육 약화의 치료
US10988744B2 (en)	2016-06-06	2021-04-27	Alexion Pharmaceuticals, Inc.	Method of producing alkaline phosphatase
JP7018933B2 (ja)	2016-08-18	2022-02-14	アレクシオンファーマシューティカルズ，インコーポレイテッド	気管気管支軟化症の治療方法
MX2019011508A (es)	2017-03-31	2019-11-01	Alexion Pharma Inc	Metodos para tratar la hipofosfatasia (hpp) en adultos y adolescentes.
WO2019131984A1 (fr) *	2017-12-28	2019-07-04	塩野義製薬株式会社	Référence pour mesure de bnp
US20190259482A1 (en) *	2018-02-20	2019-08-22	Mediedu Oy	System and method of determining a prescription for a patient
US11913039B2 (en)	2018-03-30	2024-02-27	Alexion Pharmaceuticals, Inc.	Method for producing recombinant alkaline phosphatase
EP3819638A4 (fr) *	2018-08-06	2021-11-03	Konica Minolta, Inc.	Méthode de mesure de peptide natriurétique cérébral et trousse de mesure de peptide natriurétique cérébral
JP7820148B2 (ja)	2018-08-10	2026-02-25	アレクシオンファーマシューティカルズ，インコーポレイテッド	アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法
CN111487222B (zh) *	2019-01-28	2023-11-14	上海乐合生物科技有限公司	一种检测bnp的spr芯片的制备方法
JP7407659B2 (ja) *	2019-05-30	2024-01-04	塩野義製薬株式会社	プロテアーゼ阻害剤を含有するｂｎｐ測定用標準品
MX2022007114A (es)	2019-12-09	2022-07-11	Alexion Pharma Inc	Polipeptidos de fosfatasa alcalina y metodos de uso de los mismos.
MX2023002673A (es)	2020-09-04	2023-05-12	Alexion Pharma Inc	Métodos para el tratamiento de trastornos de mineralización ósea.
EP4291224A4 (fr)	2021-02-12	2025-01-01	Alexion Pharmaceuticals, Inc.	Polypeptides de phosphatase alcaline et leurs méthodes d'utilisation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5786163A (en) *	1992-06-03	1998-07-28	Medinnova Sf	BNP antibody and immunoassay using it
US6117644A (en) *	1998-06-04	2000-09-12	Ottawa Heart Institute Research Corporation	Predicting and detecting cardiac allograft rejection
US6124430A (en) *	1996-03-04	2000-09-26	Scios Inc.	Human brain natriuretic peptides
WO2002023191A1 (fr) *	2000-09-12	2002-03-21	University Of Sydney	Dosage diagnostique
US20020055186A1 (en) *	2000-09-19	2002-05-09	Oxford Glycosciences (Uk) Ltd.	Detection of peptides

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5422393A (en)	1988-07-11	1995-06-06	Naturon Pharmaceutical Corporation	Natriuretic hormone
US5028535A (en)	1989-01-10	1991-07-02	Biosite Diagnostics, Inc.	Threshold ligand-receptor assay
US5939272A (en)	1989-01-10	1999-08-17	Biosite Diagnostics Incorporated	Non-competitive threshold ligand-receptor assays
ATE170192T1 (de) *	1989-06-23	1998-09-15	Genentech Inc	Zusammensetzungen und methoden zur synthese des b-rezeptors für das natriuretische protein und verwendungsmethoden
US5922615A (en)	1990-03-12	1999-07-13	Biosite Diagnostics Incorporated	Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (fr)	1990-09-14	1992-03-15	Kenneth Francis Buechler	Anticorps liant aux complexes de recepteurs de ligands et de ligands et leur utilite dans les tests ligand-recepteur
US5955377A (en)	1991-02-11	1999-09-21	Biostar, Inc.	Methods and kits for the amplification of thin film based assays
ATE177841T1 (de)	1991-04-10	1999-04-15	Biosite Diagnostics Inc	''crosstalk''- oder übersprech-inhibitoren und ihre verwendung
CA2107899A1 (fr)	1991-04-10	1992-10-11	Gunars Edwin Valkirs	Nouveaux conjugues et analyses pour la detection simultanee de plusieurs ligands
US5885527A (en)	1992-05-21	1999-03-23	Biosite Diagnostics, Inc.	Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en)	1992-05-21	2000-11-07	Biosite Diagnostics, Inc.	Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en)	1992-07-31	1996-02-27	Biostar, Inc.	Devices and methods for detection of an analyte based upon light interference
US5605798A (en)	1993-01-07	1997-02-25	Sequenom, Inc.	DNA diagnostic based on mass spectrometry
WO1994028418A1 (fr)	1993-05-28	1994-12-08	Baylor College Of Medicine	Procedes et dispositif de desorption et d'ionisation d'analytes
US5824799A (en)	1993-09-24	1998-10-20	Biosite Diagnostics Incorporated	Hybrid phthalocyanine derivatives and their uses
US6113855A (en)	1996-11-15	2000-09-05	Biosite Diagnostics, Inc.	Devices comprising multiple capillarity inducing surfaces
US5947124A (en)	1997-03-11	1999-09-07	Biosite Diagnostics Incorporated	Diagnostic for determining the time of a heart attack
NZ516848A (en)	1997-06-20	2004-03-26	Ciphergen Biosystems Inc	Retentate chromatography apparatus with applications in biology and medicine
GB9717926D0 (en)	1997-08-22	1997-10-29	Micromass Ltd	Methods and apparatus for tandem mass spectrometry
AU2463299A (en)	1998-01-23	1999-08-09	Analytica Of Branford, Inc.	Mass spectrometry from surfaces
EP1068356B8 (fr)	1998-04-03	2007-01-03	Adnexus Therapeutics, Inc.	Systemes de proteines adressables
US6406921B1 (en)	1998-07-14	2002-06-18	Zyomyx, Incorporated	Protein arrays for high-throughput screening
DE19847690A1 (de)	1998-10-15	2000-04-20	Brahms Diagnostica Gmbh	Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
WO2000056934A1 (fr)	1999-03-24	2000-09-28	Packard Bioscience Company	Reseaux matriciels poreux et continus
KR100713786B1 (ko)	1999-04-27	2007-05-07	바이오 래드 래버러토리스 인코오포레이티드	기체상 이온 분광계용 탐침
US6555813B1 (en)	1999-04-29	2003-04-29	Ciphergen Biosystems, Inc.	Probes with hydrophobic coatings for gas phase ion spectrometers
WO2001031580A2 (fr)	1999-10-27	2001-05-03	Biowulf Technologies, Llc	Procedes et dispositifs pouvant identifier des modeles dans des systemes biologiques, et procedes d'utilisation
AU2001280581A1 (en)	2000-07-18	2002-01-30	Correlogic Systems, Inc.	A process for discriminating between biological states based on hidden patterns from biological data
US20020182649A1 (en)	2001-02-01	2002-12-05	Ciphergen Biosystems, Inc.	Methods for protein identification, characterization and sequencing by tandem mass spectrometry
US20040126767A1 (en)	2002-12-27	2004-07-01	Biosite Incorporated	Method and system for disease detection using marker combinations
US20030219734A1 (en)	2001-04-13	2003-11-27	Biosite Incorporated	Polypeptides related to natriuretic peptides and methods of their identification and use
WO2003016910A1 (fr)	2001-08-20	2003-02-27	Biosite, Inc.	Marqueurs diagnostiques d'ictus et de lesions cerebrales et procedes d'utilisation de ces marqueurs
US7632647B2 (en)	2001-04-13	2009-12-15	Biosite Incorporated	Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
JP3806694B2 (ja) *	2001-05-04	2006-08-09	バイオサイトインコーポレイテッド	急性冠状動脈症候群の診断マーカーおよびその使用方法
US7113896B2 (en)	2001-05-11	2006-09-26	Zhen Zhang	System and methods for processing biological expression data
JP4264002B2 (ja)	2001-07-17	2009-05-13	バイオ−ラドラボラトリーズインコーポレイテッド	ラテックスベース吸着チップ
US7842498B2 (en)	2001-11-08	2010-11-30	Bio-Rad Laboratories, Inc.	Hydrophobic surface chip
AU2002366875B2 (en)	2001-12-21	2008-08-21	Sense Proteomic Limited	Probe for mass spectrometry
WO2003056344A2 (fr)	2001-12-21	2003-07-10	Sense Proteomic Limited	Cible et procede
EP1481244A4 (fr)	2002-01-25	2008-07-02	Bio Rad Laboratories	Monomeres et polymeres a groupes fonctionnels d'absorption d'energie utiles dans la desorption/ionisation d'analytes
US20020193950A1 (en)	2002-02-25	2002-12-19	Gavin Edward J.	Method for analyzing mass spectra
US20030218130A1 (en)	2002-05-02	2003-11-27	Ciphergen Biosystems, Inc.	Biochips with surfaces coated with polysaccharide-based hydrogels
WO2004076511A2 (fr)	2003-02-21	2004-09-10	Ciphergen Biosystems, Inc.	Revetements de surface d'hydrogel photoreticule

2004
- 2004-04-19 WO PCT/US2004/012067 patent/WO2004094460A2/fr not_active Ceased
- 2004-04-19 US US10/827,919 patent/US7341838B2/en not_active Expired - Fee Related
- 2004-04-19 JP JP2006513130A patent/JP2006527190A/ja not_active Ceased
- 2004-04-19 CA CA002522709A patent/CA2522709A1/fr not_active Abandoned
- 2004-04-19 EP EP04750349A patent/EP1616181B1/fr not_active Revoked
2008
- 2008-01-14 US US12/013,606 patent/US20080160540A1/en not_active Abandoned

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5786163A (en) *	1992-06-03	1998-07-28	Medinnova Sf	BNP antibody and immunoassay using it
US6124430A (en) *	1996-03-04	2000-09-26	Scios Inc.	Human brain natriuretic peptides
US6117644A (en) *	1998-06-04	2000-09-12	Ottawa Heart Institute Research Corporation	Predicting and detecting cardiac allograft rejection
WO2002023191A1 (fr) *	2000-09-12	2002-03-21	University Of Sydney	Dosage diagnostique
US20020055186A1 (en) *	2000-09-19	2002-05-09	Oxford Glycosciences (Uk) Ltd.	Detection of peptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIDZSERANOVA A ET AL: "Structure-activity studies on the effects of atrial natriuretic peptide, brain natriuretic peptide and their analogs on fear-motivated learning behavior in rats.", NEUROPEPTIDES. OCT 1992, vol. 23, no. 2, October 1992 (1992-10-01), pages 61 - 65, XP002390351, ISSN: 0143-4179 *
NORMAN J A ET AL: "Degradation of brain natriuretic peptide by neutral endopeptidase: species specific sites of proteolysis determined by mass spectrometry.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 28 FEB 1991, vol. 175, no. 1, 28 February 1991 (1991-02-28), pages 22 - 30, XP001246990, ISSN: 0006-291X *
See also references of WO2004094460A2 *
VENUGOPAL J: "Cardiac natriuretic peptides--hope or hype?", JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. FEB 2001, vol. 26, no. 1, February 2001 (2001-02-01), pages 15 - 31, XP002390352, ISSN: 0269-4727 *

Also Published As

Publication number	Publication date
US20050064511A1 (en)	2005-03-24
JP2006527190A (ja)	2006-11-30
EP1616181A2 (fr)	2006-01-18
WO2004094460A2 (fr)	2004-11-04
CA2522709A1 (fr)	2004-11-04
WO2004094460A3 (fr)	2005-01-27
EP1616181B1 (fr)	2009-08-12
US20080160540A1 (en)	2008-07-03
US7341838B2 (en)	2008-03-11

Legal Events

Date	Code	Title	Description
2005-12-02	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2006-01-18	17P	Request for examination filed	Effective date: 20051109
2006-01-18	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
2006-01-18	AX	Request for extension of the european patent	Extension state: AL HR LT LV MK
2006-07-26	DAX	Request for extension of the european patent (deleted)
2006-08-30	RIC1	Information provided on ipc code assigned before grant	Ipc: G01N 33/74 20060101ALI20060727BHEP Ipc: G01N 33/53 20060101AFI20050201BHEP Ipc: G01N 33/68 20060101ALI20060727BHEP Ipc: C07K 16/26 20060101ALI20060727BHEP
2006-09-06	A4	Supplementary search report drawn up and despatched	Effective date: 20060809
2007-02-21	17Q	First examination report despatched	Effective date: 20070119
2008-02-27	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: BIOSITE INCORPORATED Owner name: VERMILLION, INC.
2008-11-11	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2008-11-12	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 14/58 20060101AFI20081007BHEP Ipc: G01N 33/74 20060101ALI20081007BHEP
2009-06-20	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2009-07-10	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2009-08-12	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
2009-08-12	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2009-08-14	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2009-09-16	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2009-09-24	REF	Corresponds to:	Ref document number: 602004022527 Country of ref document: DE Date of ref document: 20090924 Kind code of ref document: P
2010-01-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090812 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090812 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090812 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091123
2010-02-01	NLV1	Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
2010-02-26	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090812 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090812 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090812
2010-03-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091212 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091112
2010-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090812 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090812 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090812 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090812
2010-05-21	PLBI	Opposition filed	Free format text: ORIGINAL CODE: 0009260
2010-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090812
2010-06-11	PLAX	Notice of opposition and request to file observation + time limit sent	Free format text: ORIGINAL CODE: EPIDOSNOBS2
2010-06-23	26	Opposition filed	Opponent name: BIO-RAD PASTEUR Effective date: 20100512
2010-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090812
2010-07-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20100525 Year of fee payment: 7
2010-08-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20100531 Year of fee payment: 7
2010-10-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091113
2010-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100430
2010-11-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20100507 Year of fee payment: 7
2010-11-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2010-12-03	PLBB	Reply of patent proprietor to notice(s) of opposition received	Free format text: ORIGINAL CODE: EPIDOSNOBS3
2010-12-07	RDAF	Communication despatched that patent is revoked	Free format text: ORIGINAL CODE: EPIDOSNREV1
2011-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100419
2011-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100430 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100430
2011-03-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090812
2011-04-01	RDAG	Patent revoked	Free format text: ORIGINAL CODE: 0009271
2011-04-01	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: PATENT REVOKED
2011-05-04	27W	Patent revoked	Effective date: 20101224
2011-05-04	GBPR	Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state	Effective date: 20101224
2012-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090812
2012-09-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100213 Ref country code: LU Free format text: LAPSE BECAUSE OF REVOCATION BY EPO Effective date: 20100419

Publication	Publication Date	Title
AU2003267124A8 (en)	2004-03-29	Bh3 peptides and method of use thereof
PL1615992T3 (pl)	2014-03-31	Materiały wiążące białko prionowe i sposoby ich zastosowania
HUE044812T2 (hu)	2019-11-28	Prolinspecifikus endoproteázok alkalmazása peptidek és fehérjék hidrolízisére
IL166632A0 (en)	2006-01-15	Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
WO2005072055A9 (fr)	2011-02-17	Nouveaux variants de peptides cerebraux natriuretiques et leurs procede d'utilisation
SI2656854T1 (sl)	2015-09-30	Uporabe aromatsko-kationskega peptida
IL175152A0 (en)	2006-09-05	Stabilized alpha helical peptides and uses thereof
EP1812030A4 (fr)	2009-01-14	Peptides anti-angiogeniques et procedes d'utilisation de ceux-ci
EP1786451A4 (fr)	2009-07-22	Peptides anti-angiogenes et leurs procedes d'utilisations
EP1736541A4 (fr)	2007-06-06	Proteine de modification de galectine-9 novatrice et utilisation de celle-ci
EP1794589A4 (fr)	2010-03-17	Reseaux de proteines et leurs procedes d'utilisation
GB2401094B (en)	2006-07-19	Labels and methods of manufacture thereof
AU2003247537A8 (en)	2003-12-31	Chd5 encoding nucleic acids, polypeptides, antibodies and methods of use thereof
AU2003226899A8 (en)	2003-09-29	Human diabetes-mediating proteins
AU2003231980A8 (en)	2003-10-13	Identification of apoptotic peptides and methods of use thereof
GB0309064D0 (en)	2003-05-28	Modified peptides and their uses
ZA200606216B (en)	2007-11-28	Modified human interferon polypeptides and their uses
IL177868A0 (en)	2006-12-31	Anti-inflammatory peptides and methods of use thereof
AU2003262638A8 (en)	2004-03-03	Biotinylation of proteins
AU2003262895A8 (en)	2004-03-19	Carboxypeptidase b related polypeptides and methods of use
EP1576168A4 (fr)	2010-08-25	Polypeptides therapeutiques, acides nucleiques codant ces polypeptides et procedes d'utilisation
AU2003213933A8 (en)	2008-02-28	Purified polypeptides involved in protein synthesis and modification
AU2003260487A8 (en)	2003-10-20	Novel pancortin-pablo protein interactions and methods of use thereof
EP1699809A4 (fr)	2009-10-21	Peptide provenant du liquide amniotique et ses utilisations
EP1549951A4 (fr)	2006-08-09	Proteines de type semaphorine et methodes d'utilisation de celles-ci